NCT02447328 2021-09-05A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerAstraZenecaPhase 4 Completed83 enrolled 6 charts